• Health
  • Science
  • U.S.
  • Technology
  • Business
  • World
  • Politics
  • Entertainment
  • Sports

Building a Better World

News and information

  • Home
  • Privacy Policy
  • Contact Us
  • Our Team

Women need more of this controversial drug to prevent HIV infection

March 5, 2016 By Sam Catherman

Women need more of this controversial drug to prevent HIV infection

A recent study has shown that women need more of this drug to prevent HIV than their male counterparts - here's why.

Truvada, a pill that works to prevent the spread of HIV, has been the source of quite a bit of controversy as of late. And according to a report from UPI, a recent study has stirred the pot even further. Researchers at the University of North Carolina at Chapel Hill have found that women need more of the drug than men to effectively prevent infection.

Truvada is currently the only approved drug for the prevention of HIV infection. The study, published in the Journal of Infectious Diseases, suggested that while only two doses per week was sufficient for male patients, female patients needed a daily dose in order to effectively prevent HIV transmission.

The U.S. Food and Drug Administration approved the medication in 2012, and so far the results have been positive. Treating high-risk individuals with Truvada has resulted in a significant drop in the number of new HIV infections in places where the drug is easily obtainable.

Scientists examined the level of DNA material found in human cells that HIV could use as a means to reproduce and spread throughout the body. They calculated the amount of Truvada it would take to prevent an HIV infection based on the level of available material, and discovered a huge disparity between male and female patients.

To test their calculations, they gave 47 healthy women Truvada and took samples of vaginal, cervical, and rectal tissue. They tested for the levels of Truvada and DNA material present in each woman, and found that the drug was not making its way into vaginal and cervical tissues. They reasoned that the only way to deliver enough Truvada to these critical tissues was to increase the dosage to once a day.

Truvada has been hailed for its ability to stem the spread of HIV, but has also drawn controversy from critics who say it lulls high-risk individuals into a false sense of security. It certainly doesn’t hurt, but it is important to remain vigilant about sexual health risks on all fronts.

A press release from the University of North Carolina at Chapel Hill describing the details of the study can be found here.

 

Sharing

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Filed Under: Front Page, Health

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow Us

Facebookrss

Search:

Recent Posts

  • NASA’s InSight spacecraft makes important course correction May 26, 2018
  • Scientists outraged at latest Trump decision May 15, 2018
  • Huge uproar erupts over major incident at Utah park May 13, 2018
  • Incredible moon discovery stuns scientists May 12, 2018
  • Authorities shocked by discovery about common painkiller May 6, 2018
  • Outrageous crocodile experiment stuns scientists May 5, 2018
  • Great Barrier Reef is too quiet, scientists say May 1, 2018
  • Massive Hiroshima bomb discovery shocks scientists May 1, 2018
  • Earth will be slammed by massive asteroid April 29, 2018
  • Teens are doing something incredibly alarming in schools April 29, 2018
  • Huge discovery in Tasmania stuns scientists April 28, 2018
  • Shocking discovery in New Jersey stuns authorities April 22, 2018
  • Huge volcanic explosion could wipe out the United States April 21, 2018
  • Huge controversy erupts over world’s hottest pepper April 15, 2018
  • SpaceX is about to do something astonishing April 15, 2018

Copyright © 2022 Jones Kilmartin Group, LLC · Metro Pro Theme On Genesis Framework · WordPress